O.K to be really clear understand this... 1. The funds are used...

O.K to be really clear understand this...

1. The funds are used for Sofdra (Not to advance pipeline, or get Sofdra into other territories) this is just for SOFDRA in the next two quarters.

"The proceeds from the Placement will be applied towards funding the launch of Sofdra™ in the United
States. Specifically, the Placement will fund sales force and marketing infrastructure as well as digital
marketing costs and the telemedicine platform (‘sales and marketing costs’), manufacturing costs, as
well as new quality assurance, pharmacovigilance and support services (‘support costs’), working
capital and costs of the Placement."

2. Revenue will not flow until September - or last quarter of 2024.

"Manufacturing and labeling of Sofdra™ will likely take approximately 4-5 weeks to complete before product is shipped to
Botanix’s warehouse, for distribution to US pharmacies to support the early patient experience
program.

An early patient experience program is planned to be launched by the Company in Q3 CY2024 to
enable highly qualified patients to gain early access to Sofdra™...Broader launch of Sofdra™ is expected to follow in early Q4 CY2024 and Botanix expects to receive first revenues from sales in Q4 CY2024.

Temper expectations - it will happen all in good time.

DYOR and all that - just opinions